Format

Send to

Choose Destination
Ann Transl Med. 2018 Feb;6(3):61. doi: 10.21037/atm.2017.12.27.

Osimertinib, the winner, but cannot yet take it all.

Author information

1
Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Conflict of interest statement

Conflicts of Interest: DH Lee declared that he received honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CJ Healthcare, Eli Lilly, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm and ST Cube. He also has a consulting role in Ministry of Food and Drug Safety, Korea; Health Insurance Review and Assessment Service, Korea; National Evidence-based Collaborating Agency, Korea; and National Cancer Control Planning Board, Korea. The other authors have no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center